8-K: Select Medical Reports Strong Q2 Earnings, Reaffirms 2025 Outlook

Select Medical Holdings Corporation announced robust second-quarter 2025 financial results, including significant increases in net income and earnings per share from continuing operations, while reaffirming its full-year 2025 business outlook.

Summary

• Revenue for the second quarter ended June 30, 2025, increased 4.5% to $1,339.6 million, compared to $1,281.7 million for the same quarter in the prior year.
• Income from continuing operations, net of tax, for Q2 2025 increased 53.8% to $57.9 million, up from $37.6 million in the prior year's second quarter.
• Earnings per common share from continuing operations for Q2 2025 rose 88.2% to $0.32, compared to $0.17 for the same quarter in the prior year.
• Adjusted EBITDA for Q2 2025 increased 0.5% to $125.4 million, compared to $124.7 million in the prior year's second quarter.
• For the six months ended June 30, 2025, revenue increased 3.4% to $2,692.8 million, and income from continuing operations, net of tax, increased 33.7% to $132.6 million.
• Earnings per common share from continuing operations for the six months ended June 30, 2025, increased 52.0% to $0.76.
• The Board of Directors declared a cash dividend of $0.0625 per share, payable on or about August 28, 2025, to stockholders of record as of August 13, 2025.
• The company reaffirmed its 2025 business outlook, expecting revenue in the range of $5.3 billion to $5.5 billion, Adjusted EBITDA between $510.0 million and $530.0 million, and fully diluted earnings per share from $1.09 to $1.19.
• During the six months ended June 30, 2025, Select Medical repurchased 6,375,512 shares at a cost of approximately $96.5 million, or $15.13 per share, under its $1.0 billion common stock repurchase program, which remains in effect until December 31, 2025.

Sentiment

Score: 8

Explanation: The sentiment is positive due to strong growth in overall revenue, income from continuing operations, and earnings per share. The reaffirmation of the full-year outlook and active capital return through dividends and share repurchases further bolster confidence, despite some segment-specific declines.

Positives

• Overall revenue increased by 4.5% for Q2 2025 and 3.4% for the six months ended June 30, 2025.
• Income from continuing operations, net of tax, significantly increased by 53.8% in Q2 2025 and 33.7% for the six months ended June 30, 2025.
• Earnings per common share from continuing operations showed strong growth, up 88.2% in Q2 2025 and 52.0% for the six months ended June 30, 2025.
• The Rehabilitation Hospital segment demonstrated robust growth with revenue up 17.2% and Adjusted EBITDA up 14.7% in Q2 2025.
• The Outpatient Rehabilitation segment also showed positive performance with revenue up 3.8% and Adjusted EBITDA up 6.1% in Q2 2025.
• The company declared a cash dividend of $0.0625 per share, indicating a commitment to shareholder returns.
• An active stock repurchase program is in place, with $96.5 million in shares repurchased during the first half of 2025, returning capital to shareholders.
• The overall occupancy rate for Critical Illness Recovery Hospitals increased to 69% in Q2 2025 from 67% in the prior year.

Negatives

• The Critical Illness Recovery Hospital segment experienced a revenue decrease of 0.6% and a significant Adjusted EBITDA decline of 21.6% in Q2 2025.
• The Adjusted EBITDA margin for the Critical Illness Recovery Hospital segment decreased to 9.4% in Q2 2025 from 11.9% in the prior year.
• Adjusted EBITDA for the six months ended June 30, 2025, decreased by 4.7% to $276.9 million compared to $290.5 million in the prior year period.
• The Adjusted EBITDA margin for the Rehabilitation Hospital segment slightly decreased to 22.6% in Q2 2025 from 23.1% in the prior year.
• The Adjusted EBITDA margin for the Outpatient Rehabilitation segment slightly decreased to 8.6% for the six months ended June 30, 2025, from 8.7% in the prior year period.

Risks

• Changes in government reimbursement for services and/or new payment policies may result in a reduction in revenue, an increase in costs, and a reduction in profitability.
• Adverse economic conditions, including an inflationary environment, could cause continued increases in the prices of labor and other business costs, negatively impacting business, operating results, cash flows, and financial condition.
• Changes to United States tariff and import/export regulations and their impact on global economic conditions may negatively affect business, financial condition, and results of operations.
• Shortages in qualified nurses, therapists, physicians, or other licensed providers, and/or the inability to attract or retain qualified healthcare professionals could limit the ability to staff facilities.
• Increased dependence on contract labor, increased recruitment and training efforts, and expanded initiatives to retain existing staff due to professional shortages could significantly increase operating costs.
• The negative impact of public threats such as a global pandemic or widespread outbreak of an infectious disease.
• Failure of Medicare-certified long-term care hospitals or inpatient rehabilitation facilities to maintain their Medicare certifications may cause revenue and profitability to decline.
• Failure of Medicare-certified long-term care hospitals and inpatient rehabilitation facilities operated as hospitals within hospitals to qualify as hospitals separate from their host hospitals may cause revenue and profitability to decline.
• A government investigation or assertion of regulatory violations may result in sanctions, reputational harm, and increased costs.
• Acquisitions or joint ventures may prove difficult or unsuccessful, use significant resources, or expose the company to unforeseen liabilities.
• Private third-party payors for services may adopt payment policies that could limit future revenue and profitability.
• Failure to maintain established relationships with physicians in the areas served could reduce revenue and profitability.
• Competition may limit growth and result in a decrease in revenue and profitability.
• The loss of key members of the management team could significantly disrupt operations.
• Claims asserted against the company could subject it to substantial uninsured liabilities.
• A security breach of the company's or third-party vendors' information technology systems may subject the company to potential legal and reputational harm and may result in a violation of healthcare privacy acts.

Future Outlook

The company reaffirmed its 2025 business outlook, expecting full fiscal year revenue to be in the range of $5.3 billion to $5.5 billion, Adjusted EBITDA to be between $510.0 million and $530.0 million, and fully diluted earnings per share to be in the range of $1.09 to $1.19.

Management Comments

• No direct quotes from company management were provided in the filing, but the reaffirmation of the 2025 business outlook implies confidence in the company's financial trajectory.

Industry Context

The healthcare industry continues to experience evolving dynamics, including shifts in patient demand, reimbursement policies, and persistent labor cost pressures. Select Medical's mixed segment performance, with strong growth in rehabilitation and outpatient services offsetting declines in critical illness recovery, reflects the diverse challenges and opportunities within the post-acute care sector. The company's focus on expanding its rehabilitation hospital footprint and maintaining outpatient services aligns with broader trends towards value-based care and community-based treatment options, while the critical illness segment faces specific operational headwinds.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to benchmark Select Medical's performance against industry standards.

Legal Proceedings

• The company faces potential risks from government investigations or assertions of regulatory violations that could result in sanctions or reputational harm.
• The company is exposed to potential substantial uninsured liabilities from claims asserted against it.

Stakeholder Impact

• Shareholders benefit from increased earnings per share from continuing operations, the declared cash dividend, and the ongoing share repurchase program, which enhances shareholder value.
• Employees face potential risks related to shortages of qualified healthcare professionals, which could lead to increased workload or reliance on contract labor.
• Patients are directly impacted by the company's operations across its critical illness recovery hospitals, rehabilitation hospitals, and outpatient rehabilitation clinics, with service availability and quality being key factors.

Next Steps

• Host a conference call on August 1, 2025, at 9:00am ET to discuss second quarter results and business outlook.
• Pay the declared cash dividend on or about August 28, 2025, to stockholders of record as of August 13, 2025.
• Continue the common stock repurchase program, which is authorized until December 31, 2025.

Key Dates

Recommendation

The company demonstrated strong financial performance in Q2 2025, with significant increases in revenue, income from continuing operations, and EPS from continuing operations. The reaffirmation of the full-year 2025 outlook provides stability and confidence in future performance. While the critical illness recovery hospital segment showed some weakness, the robust growth in rehabilitation and outpatient segments, coupled with an active share repurchase program and dividend declaration, indicates a healthy and shareholder-friendly capital allocation strategy. These factors suggest a positive outlook for the stock.

Keywords

Healthcare, Rehabilitation, Hospitals, Outpatient clinics, Critical illness recovery, Financial results, Earnings, Dividend, Stock repurchase, SEC filing, SEM